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Abstract
Background
Increased availability of Next Generation Sequencing (NGS) techniques allows, for the first time,
to distinguish relapses from reinfections in patients with multiple Buruli ulcer (BU) episodes.
Methodology
We compared the number and location of single nucleotide polymorphisms (SNPs) identi-
fied by genomic screening between four pairs ofMycobacterium ulcerans isolates collected
at the time of first diagnosis and at recurrence, derived from a collection of almost 5000 well
characterized clinical samples from one BU treatment center in Benin.
Principal Findings
The findings suggest that after surgical treatment—without antibiotics—the second epi-
sodes were due to relapse rather than reinfection. Since specific antibiotics were introduced
for the treatment of BU, the one patient with a culture available from both disease episodes
hadM. ulcerans isolates with a genomic distance of 20 SNPs, suggesting the patient was
most likely reinfected rather than having a relapse.
Conclusions
To our knowledge, this study is the first to study recurrences inM. ulcerans using NGS, and
to identify exogenous reinfection as causing a recurrence of BU. The occurrence of reinfec-
tion highlights the contribution of ongoing exposure toM. ulcerans to disease recurrence,
and has implications for vaccine development.
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Author Summary
We compared the whole genomes of four pairs ofMycobacterium ulcerans isolates col-
lected at the time of first diagnosis and at recurrence, derived from a collection of almost
5000 well characterized clinical samples from one BU treatment center in Benin. Our find-
ings suggest that after surgical treatment—without antibiotics—the second episodes were
due to relapse rather than reinfection. Since specific antibiotics were introduced for the
treatment of BU, the one patient with a culture available from both disease episodes had
M. ulcerans isolates with a larger genomic distance, suggesting that the patient was most
likely reinfected rather than having a relapse. To our knowledge, this study is the first to
assess recurrences inM. ulcerans using whole genomes, and to identify exogenous reinfec-
tion as causing a recurrence of BU. The occurrence of reinfection highlights the contribu-
tion of ongoing exposure toM. ulcerans to disease recurrence, and has implications for
vaccine development.
Introduction
Buruli ulcer (BU) is a neglected necrotizing skin and bone disease caused by the enigmatic
pathogenMycobacterium ulcerans that occurs in riverine regions of West and Central Africa.
The clonal nature ofM. ulcerans has complicated molecular analyses of the epidemiology of
the pathogen, as genotyping methods with sufficient resolution have been lacking [1]. Using
insertion sequence element single nucleotide polymorphism (ISE-SNP) typing, a technique in
which two relatively small regions (1,431 and 1,871 bp) of theM. ulcerans genome are screened
for polymorphisms, strains could be distinguished to the level of the river basin in West Africa
[2]. However, such molecular genotyping techniques lack sufficient resolution to distinguish
relapse from reinfection with an unrelated exogenous strain ofM. ulcerans among BU recur-
rences. The World Health Organization (WHO) defines a relapse as a recurrence of BU within
one year after termination of antibiotic treatment [3]. A recurrence that appears after that
period is consequently considered a reinfection. The contribution of relapses versus reinfec-
tions to BU recurrences and their biological basis are to date unknown.
Until the routine use of antibiotics (rifampicin and streptomycin) was advocated by the
WHO in 2004, surgery was the mainstay of BU therapy. After surgical treatment only, a recur-
rence rate of 6% was reported in Benin [4,5]. Higher recurrence rates were reported in Ghana
(16%-35%) [6,7], Ivory Coast (17%) [8], Uganda (20%) [9], and Australia (32%) [10]. When
specific antibiotics are used very few, if any, recurrences are observed [11–13].
The introduction of Next Generation Sequencing (NGS) now allows for the first time to distin-
guish relapses from reinfections in patients with multiple BU episodes. Similar studies have been
conducted forMycobacterium tuberculosis [14,15] and other monomorphic bacterial infections,
such as Clostridium difficile [16]. In the present study we compared the number and location of
SNPs identified by genomic screening between four pairs ofM. ulcerans isolates collected at the
time of first diagnosis and at recurrence, derived from a collection of almost 5000 well character-
ized clinical samples from one BU treatment center in Zagnanado, Benin, between 1989 and 2010.
Methods
Study design and participants
We defined an episode as a clinical suspicion of BU and a recurrence as the presence of two epi-
sodes separated by at least six months. Four such patients were identified for this study.
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We compared the number of SNP differences separating the paired isolates and a random
selection of 36 isolates from 36 patients living in the same geographical area and diagnosed
with BU in the same time frame (1998–2008) as the patients with multiple episodes. We also
compared genomic relatedness between six patients with twoM. ulcerans cultures isolated
from the same disease episode. This genetic background helped to avoid misclassifying any sec-
ond episodes with similarM. ulcerans strains prevalent in the patient’s environment as relapses
rather than reinfections. As such a total of 58M. ulcerans isolates obtained from 46 patients
was included in this study (Fig 1).
Genome sequencing and analysis
DNA was obtained by harvesting the growth of three Löwenstein-Jensen slants followed by
heat inactivation, mechanical disruption, enzymatic digestion and DNA purification on a Max-
well 16 automated platform, a technique modified from Käser et al. [17].
Whole genome sequencing of the isolates was performed using an Illumina HiSeq 2000
DNA sequencer and an Illumina MiSeq DNA sequencer with Nextera XT or TruSeq (Illumina
Inc., San Diego, CA, USA) library preparation and 2x36bp 2x100bp 2x150bp 2x250bp sequenc-
ing paired-end chemistry. Sequencing statistics are provided in S1 Table.
The sequencing data analysis was done using the Nesoni software [18]. Firstly, reads were
filtered to remove those containing ambiguous base calls, any reads<50 nucleotides in length,
and reads containing only homopolymers. All reads were furthermore trimmed removing
residual ligated Nextera of TruSeq adaptors and low quality bases (<Q10) at the 3' end. Aver-
age read lengths after clipping are summarized for all isolates in S1 Table. Bowtie2 v2.1.0 [19]
was used with default parameters to map clipped sequence reads sets to the GhanaianM. ulcer-
ans Agy99 reference genome (Genbank accession number: CP000325). Due to the unreliability
of read mapping in repetitive regions, all ISE elements (IS2404 and IS2606) were hard masked
in this reference genome. Average read depths after mapping toM. ulcerans Agy99 are summa-
rized for all isolates in S1 Table.
We compared the number and location of SNPs between isolates collected at baseline and at
recurrence. At each of the loci called as a variant in any read set, Nesoni was used to generate a
multi-way summary of consensus allele calls at the corresponding locus in all other read sets of
the investigated panel. By concatenating all these loci a multiple SNP sequence alignment was
generated containing all 282 variant loci across the Agy99 reference chromosome sequence. A
Fig 1. Flow chart outlining theM. ulcerans isolates included in this analysis.
doi:10.1371/journal.pntd.0004158.g001
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maximum likelihood (ML) phylogenetic tree was constructed from this alignment using
RAxML v8.0.19 [20] under a GTR model of evolution (no rate heterogeneity) and with an
ascertainment bias likelihood correction for SNP data. The resulting tree was visualized in Fig-
tree v1.4.0 [21] with nodes of interest highlighted. A haplotype network was derived using the
median joining algorithm [22] as implemented within SplitsTree v.4.13.1 [23] with default set-
tings. This network was subsequently visualized with Hapstar v.0.7 [24].
The open source geographic information system Quantum GIS (QGIS v1.8.0) [25] was used
to generate the illustration of the geographical distribution of all includedM. ulcerans genomes
in Fig 2. The geographical locations of the residences of BU patients at the time of their first
consultation are shown. The river layer (Ouémé river and its tributaries) was digitized from
declassified Soviet military topographic maps b31-03, b31-09, and b31-15 (scale 1:200k). The
administrative borders of African countries were rendered from the Global Administrative
Unit Layers data set of FAO [26].
Ethics
This retrospective study on stored isolates was approved by the Institutional Review Board of
the Institute of Tropical Medicine.
Accession numbers
Read data for the study isolates have been deposited in the NCBI Sequence Read Archive
(SRA) under accession n° PRJNA296792.
Results
Among the 4951 clinically BU suspected patients who consulted the BU treatment centre of
Gbemotin in Zagnanado in southern Benin between 1989 and 2010, we identified 100 who pre-
sented with multiple BU episodes (Fig 3). A majority of 93 patients had two disease episodes
while 7 had three episodes. Twenty recurrence patients received streptomycin and/or rifampi-
cin during their first BU episode. The distribution of patients that had received (partially) effec-
tive antibiotics is shown in the S1 Fig. Only for seven of the 100 recurrence patients were we
able to successfully culture isolates from each of two or three disease episodes, owing to the lim-
ited sensitivity of culture for isolation ofM. ulcerans from skin biopsies [27]. These mycobacte-
rial isolates were stored at70°C in Dubos broth enriched with growth supplement and
glycerol. However, paired cultures were found to be viable for only four of these seven patients.
The first two patients of these four patients each had three paired isolates while the other two
patients each had two (Table 1).
We assessed the pairedM. ulcerans isolates of four patients (letter-coded from A to D) with
two BU episodes each (Table 1). Each of these 4 patients presented for the first time at the BU
treatment centre of Gbemotin between 1999 and 2004. Patients A & B had lesions at the same
location during both episodes, while patients C & D had lesions at another body site. The time
between the diagnoses of both episodes ranged from seven months to almost two years. All
patients underwent surgery, while patient D also received specific antibiotics, which were intro-
duced for the routine management of BU in 2004 [3]. Comparative genomic analysis identified
two patients (B & C) with no detectable genetic differences (0 SNPs) between isolates originat-
ing from two disease episodes. Patient A had one SNP difference between his first episode iso-
late and both second episode isolates although at different positions, suggesting that micro-
evolution took place. For patient D however the isolates of both disease episodes were differen-
tiated from each other by no less than 20 SNPs, which were found distributed throughout the
genome. This is a genetic distance similar to that observed between different isolates from the
Genomics for Buruli Ulcer Recurrences
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Fig 2. A: Geographical origin of the 58 isolates included in the study. Patients of special interest are colored accordingly. The size of the dots is
proportional to the number of patients originating from a specific village varying from 1 to 3. The Ouémé river and its tributaries, and the BU treatment center
of Zagnanado are shown as well. B: Median-Joining network showing patterns of descent among the 58 studiedM. ulcerans isolates. Each circle represents
Genomics for Buruli Ulcer Recurrences
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004158 November 30, 2015 5 / 10
same geographic region as illustrated in the haplotype network (Fig 2B) and the phylogenetic
tree (red nodes, S2 Fig). The difference in SNPs between control patients varied from 0 to 53
SNPs. To exclude cross-contamination of theM. ulcerans culture obtained from the second
episode of patient D, the genome obtained from a strongly positive biopsy that was treated on
the same day as the biopsy of patient D was sequenced as well and found to differ by 21 SNPs.
There were 2 clusters of 5 and 4 patients having identicalM. ulcerans genomes, who lived in
an area of respectively 70 km² (4.7–27 km between villages) and 14 km² (3–18 km between vil-
lages). Four patients with multipleM. ulcerans isolates from the same BU episode had identical
paired genomes while one such patient differed in 1 SNP and another one in 6 SNPs between
the paired genomes with respectively 8 and 7 days between the times of sampling of the biop-
sies from which theM. ulcerans cultures were isolated (Fig 2B).
Among the total of 24 substitutions that were identified in patient A and patient D, four
occurred in intergenic regions, while 20 were found in coding sequences resulting in 3 synony-
mous changes (i.e. ‘silent’ changes) and 17 non-synonymous changes (i.e. resulting in a change
in amino acid), in genes encoding proteins with various functions (S2 Table).
Discussion
This study is the first to study recurrences inM. ulcerans using NGS, and to identify exogenous
reinfection as causing a recurrence of BU. In relapses, paired isolates are genetically more
related to each other than to isolates from other patients living in the same region and infected
a unique genotype, and the size of the circle is proportional to the number of individuals sharing that type. Every edge represents a single mutational step (or
SNP) separating the sampled and hypothetical genotypes. Genotypes obtained from patients of special interest are colored accordingly.
doi:10.1371/journal.pntd.0004158.g002
Fig 3. Flow chart outlining the patients contributing isolates to this analysis. SM: streptomycin; RMP: rifampicin.
doi:10.1371/journal.pntd.0004158.g003
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during the same time-period. In reinfections on the other hand, paired isolates are potentially
not more related to each other than to isolates from other patients living in the same region
and infected during the same time-period.
Our results suggest that the second BU episode of patients A, B and C was most likely due
to relapses. The second BU episode of the 4th patient was probably due to a reinfection. This
patient is also the only one who had received specific antibiotics during his first BU episode.
We can however not be entirely certain that patients A, B and C were not infected a second
time by an identicalM. ulcerans strain, as we identified other genetically identical clusters
among patients living in the same area and time period. As the mode of transmission ofM.
ulcerans remains enigmatic, detailed investigation of these genetic clusters may provide leads
to a common point source of exposure.
To our knowledge, this study is the first using NGS to assess recurrences inM. ulcerans,
which is important to understand BU epidemiology. In BU, when disease re-occurs within one
year after the end of treatment it is assumed to be a relapse which is considered the primary
endpoint in several studies [11–13] and in patient management. This study for the first time
indicates that exogenous reinfection plays a role in recurrence of BU. However, the restricted
phylogeny presented here based on four patients should be interpreted with some circumspec-
tion because of the limited sample size, which is due to the overall low recurrence rate at this
treatment center, combined with the low sensitivity of in vitro culture ofM. ulcerans.
In other mycobacterial infections, most notably infection withM. tuberculosis, the number
of different SNPs between relapse and reinfection pairs can be large, with a clear distinction
between pairs with a small difference (6 SNPs), classified as probably relapses, and those with
a large difference (1306 SNPs), deemed to be reinfections [15]. Epidemiologically linkedM.
tuberculosis populations have been reported with a mean SNP difference of 3.4 demonstrating
high genomic stability [28]. Walker and colleagues [29] reported that in patients with an epide-
miological link the divergence between theirM. tuberculosis genomes generally does not exceed
14 SNPs, with most patients having fewer than 5 SNP differences during one disease episode.
During recurrences of Clostridium difficile infection, paired isolates2 SNPs apart were
Table 1. Details on the four patients with recurrent BU.
ID Patient A Patient B Patient C Patient D
Gender M F M M
Age at ﬁrst consultation 12y 9y 18y 10y
Time between two episodes 9.5 months 7 months 22,5 months 9 months
Episode 1 location right lower limb left lower limb left upper limb left back/ﬂank
date of presentation 7-Apr-1999 10-Jul-2000 27-May-2002 1-Mar-2004
treatment PCN GM CXA GM CXA GM CXA SM RMP
surgery surgery surgery surgery
cultures stored 1 1 1 1
ITM992421 ITM001249 ITM021902 ITM041698
Episode 2 location right lower limb left lower limb left lower limb right buttock
cultures stored 2 2 1 1
ITM000562 ITM010548 ITM041716 ITM051516
ITM000563 ITM010623
SNP difference 1 0 0 20
PCN: penicillin; GM: gentamycin; CXA: cloxacillin, SM: streptomycin, RMP: rifampicin.
doi:10.1371/journal.pntd.0004158.t001
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considered relapses while paired isolates>10 SNPs apart were considered reinfections [16]. In
the present study we detected only one genomic difference between the relapse pairs, reaffirm-
ing the high genomic stability previously reported forM. ulcerans [1].
Apparent reinfections could theoretically result from differential sampling of an initially
mixed infection. Patient D could possibly have had a simultaneous infection by twoM. ulcerans
strains although the results from the 6 patients with multiple isolates from one BU episode sug-
gest that differentM. ulcerans strains causing a single disease episode is, at best, an infrequent
occurrence. The same was observed among four Cameroonian BU patients with multiple iso-
lates from one BU episode [30]. This suggests mixed infection would have been an unlikely
explanation for the genetic differences between the paired isolates of patient D.
The occurrence of reinfection highlights the contribution of ongoing exposure toM. ulcer-
ans to disease recurrence. Since the delay between relapse (7, 9.5, and 22.5 months) and rein-
fection (9 months) episodes overlap, the use of NGS on cultured isolates is required to
distinguish these two scenarios. BU recurrences within a period of one year after antibiotic
treatment that are considered relapses by WHO [3] may therefore also be reinfections.
Since BU transmission is probably not human-to-human and the mode of transmission
from the environment is not yet clarified, epidemiological links in support of transmission
routes are speculative at best. However, we expect to be able to determine a SNP-threshold
which can be interpreted as an epidemiological link consistent with a common source of infec-
tion in an ongoing study with a greater number ofM. ulcerans genomes from the Ouémé river
valley. The definition of transmission clusters could help to unravel the enigmatic transmission
routes ofM. ulcerans.
NGS of pairedM. ulcerans strains collected from patients with multiple episodes of BU has
sufficient resolution to distinguish relapse from reinfection. Our results on a small number of
patients suggest that after surgical treatment without antibiotics the second episodes were due
to relapse rather than reinfection. Since specific antibiotics were introduced for the treatment
of BU, the only patient with a culture available from both disease episodes hadM. ulcerans iso-
lates with a greater genetic distance, suggesting this patient was most likely reinfected.
Supporting Information
S1 Fig. Proportion of clinical suspects that had either not received any specific antibiotics
or (partially) effective antibiotics (rifampicin, streptomycin, amikacin or clarithromycin)
during their first disease episode stratified by delay between episodes (6 months: cutoff in
this study; 12 months: WHO cutoff).
(TIF)
S2 Fig. Unrooted phylogenetic SNP tree: RAxML was used to build a maximum likelihood
tree from the genomic SNP data with 282 variable positions among 58 genomes. Nodes of
interest are colored according to subject. The scale indicates expected number of substitutions
per site.
(TIF)
S1 Table. Sequencing statistics of the study isolates.
(XLSX)
S2 Table. Description of substitutions in patients A and D.
(XLSX)
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